CIR circadian technologies limited
Add to My Watchlist 0.00% ! 31.0¢

News: Circadian's continuing clinical development

  1. FNN News
    lightbulb Created with Sketch. 1
    clock Created with Sketch.
    19/12/11
    11:29
    Post #: 9458306
    .

    Circadian Technologies (ASX:CIR) CEO and managing director, Robert Klupacs updates listeners on the medical technology's operations. He says the recent clearance from the US Food and Drug Administration to trial VGX-100, a cancer treatment drug designed to starve tumours and halt their growth, has key opinion leaders worldwide "very very excited" after after "tremendous results" from pre-trial clinical testing.

     

    Klupacs also gives an update on Circadian's relationships with Healthscope, Cincinnati Children's Hospital Medical Centre, Eli Lily and Ark Therapeutics, and outlines the company's focus for 2012.
    CIR Price at posting: 45.0¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Strategic investment secured for QLD and NSW bauxite projects
right-arrow Created with Sketch.
NEWS Drilling to commence at FAU’s Gimlet high-grade gold project following approvals
right-arrow Created with Sketch.
NEWS Marquee declares maiden antimony resource at Eastern Hills with phase two exploration to commence
right-arrow Created with Sketch.
NEWS Askari sells Burracoppin Gold Project to Forrestania Resources
right-arrow Created with Sketch.
NEWS New channel sampling confirms further copper at Graceland, Namibia
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.